Ramirez Robert A, Thomas Katharine, Jacob Aasems, Lin Karen, Bren-Mattison Yvette, Chauhan Aman
Department of Medicine-Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Department of Hematology and Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States.
World J Clin Oncol. 2021 Aug 24;12(8):664-674. doi: 10.5306/wjco.v12.i8.664.
Pulmonary neuroendocrine neoplasms (NENs) represent a minority of lung cancers and vary from slower growing pulmonary carcinoid (PC) tumors to aggressive small cell lung cancer (SCLC). While SCLC can account for up to 15% of lung cancer, PCs are uncommon and represent about 2% of lung cancers. Surgical resection is the standard of care for early-stage PCs and should also be considered in early stage large cell neuroendocrine carcinoma (LCNEC) and SCLC. Adjuvant treatment is generally accepted for aggressive LCNEC and SCLC, however, less well established for PCs. Guidelines admit a lack of trials to support a high-level recommendation for adjuvant therapy. This manuscript will discuss the role for adjuvant therapy in NENs and review the available literature.
肺神经内分泌肿瘤（NENs）占肺癌的少数，范围从生长较慢的肺类癌（PC）肿瘤到侵袭性小细胞肺癌（SCLC）。虽然SCLC可占肺癌的15%，但PCs并不常见，约占肺癌的2%。手术切除是早期PCs的标准治疗方法，早期大细胞神经内分泌癌（LCNEC）和SCLC也应考虑手术切除。辅助治疗一般被认为适用于侵袭性LCNEC和SCLC，但对PCs的应用尚不明确。指南承认缺乏支持辅助治疗高级别推荐的试验。本文将讨论辅助治疗在NENs中的作用并综述现有文献。
